GSK committed up to $750 million to acquire global rights to Chimagen’s Phase 1-ready trispecific T-cell engager program for multiple myeloma. The deal expands GSK’s immuno-oncology pipeline with an asset designed to engage three targets, with the company positioning the approach as potentially advantageous versus existing two-target formats. GSK previously struck an earlier licensing deal with Chimagen for an antibody program, and the latest commitment reflects renewed confidence based on continued development progress. The move underscores that multi-target T-cell engaging strategies remain a central theme for large-company oncology portfolios, even as developers increasingly compare mechanisms and clinical differentiation across similar bispecific/trispecific classes.